Genmab A/S(GMAB)Earnings, Financials & Key Ratios
GMAB•NASDAQ
$27.54
$16.96B mkt cap·14.4× P/E·Price updated May 6, 2026
AboutGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Show more
- Revenue$21.53B+30.7%
- EBITDA$7.12B+28.0%
- Net Income$7.84B+80.2%
- EPS (Diluted)12.14+83.9%
- Gross Margin95.42%-3.2%
- EBITDA Margin33.06%-2.1%
- Operating Margin31.14%-3.6%
- Net Margin36.44%+37.9%
- ROE22.97%+55.4%
- ROIC22.16%-1.5%
- Debt/Equity0.03+15.1%
- Interest Coverage55.86-71.7%
GMAB Key Insights
Genmab A/S (GMAB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y profit CAGR of 29.4%
- ✓FCF machine: 35.2% free cash flow margin
- ✓Strong 5Y sales CAGR of 32.0%
- ✓Good 3Y average ROE of 19.9%
- ✓Healthy 5Y average net margin of 36.5%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
GMAB Price & Volume
Genmab A/S (GMAB) stock price & volume — 10-year historical chart
Loading chart...
GMAB Growth Metrics
Genmab A/S (GMAB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years38.14%
5 Years32.03%
3 Years36.75%
TTM21.03%
Profit CAGR
10 Years38.53%
5 Years29.35%
3 Years38.43%
TTM185.54%
EPS CAGR
10 Years36.77%
5 Years28.99%
3 Years39.42%
TTM45.85%
Return on Capital
10 Years22.91%
5 Years22.18%
3 Years20.04%
Last Year18.29%
GMAB Recent Earnings
Genmab A/S (GMAB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 9/12 qtrs (75%)
Q1 2026Latest
Feb 17, 2026EPS
$0.05
Est $0.46
-89.1%
Revenue
$1.1B
Est $1.1B
-0.8%
Q4 2025
Nov 6, 2025EPS
$0.65
Est $0.48
+35.4%
Revenue
$1.0B
Est $1.0B
+1.1%
Q3 2025
Aug 7, 2025EPS
$0.54
Est $0.39
+38.5%
Revenue
$925M
Est $953M
-2.9%
Q2 2025
May 8, 2025EPS
$0.31
Est $0.23
+34.8%
Revenue
$726M
Est $755M
-3.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 17, 2026 | $0.05vs $0.46-89.1% | $1.1Bvs $1.1B-0.8% |
| Q4 2025 | Nov 6, 2025 | $0.65vs $0.48+35.4% | $1.0Bvs $1.0B+1.1% |
| Q3 2025 | Aug 7, 2025 | $0.54vs $0.39+38.5% | $925Mvs $953M-2.9% |
| Q2 2025 | May 8, 2025 | $0.31vs $0.23+34.8% | $726Mvs $755M-3.9% |
Based on last 12 quarters of dataView full earnings history →
GMAB Peer Comparison
Genmab A/S (GMAB) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 REGN | 72.97B | 702.33 | 16.93 | 0.99% | 29.65% | 14.32% | 5.59% | 0.09 |
 SRPT | 2.28B | 21.79 | 9.31 | 52.97% | -11.25% | -20.57% | 0.88 | |
 INCY | 19.47B | 97.47 | 15.21 | 21.22% | 26.71% | 29.31% | 6.96% | 0.01 |
 EXEL | 11.28B | 44.42 | 15.98 | 6.98% | 35.08% | 40.21% | 7.48% | 0.08 |
 HALO | 7.76B | 65.87 | 25.73 | 37.55% | 22.69% | 6.49% | 8.31% | |
 ABBV | 364.63B | 206.15 | 86.98 | 8.57% | 6.91% | 62.15% | 4.89% | |
 BMY | 116.22B | 56.92 | 16.50 | -0.22% | 15.01% | 38.96% | 11.05% | 2.55 |
 MRK | 279.49B | 113.16 | 15.54 | 1.18% | 28.12% | 36.14% | 4.42% | 0.96 |
Compare GMAB vs Peers
Genmab A/S (GMAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GMAB Income Statement
Genmab A/S (GMAB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.82B | 2.37B | 3.03B | 5.37B | 10.11B | 8.42B | 14.51B | 16.47B | 21.53B | 14.04B |
| Revenue Growth % | 60.29% | 30.25% | 27.89% | 77.38% | 88.43% | -16.75% | 72.33% | 13.57% | 30.67% | 21.03% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 226M | 985M | 798.21M |
| COGS % of Revenue | - | - | - | - | - | - | - | 1.37% | 4.58% | - |
| Gross Profit | 1.82B▲ 0% | 2.37B▲ 30.2% | 3.03B▲ 27.9% | 5.37B▲ 77.4% | 10.11B▲ 88.4% | 8.42B▼ 16.8% | 14.51B▲ 72.3% | 16.25B▲ 12.0% | 20.54B▲ 26.4% | 13.24B▲ 0% |
| Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 98.63% | 95.42% | 94.31% |
| Gross Profit Growth % | 60.29% | 30.25% | 27.89% | 77.38% | 88.43% | -16.75% | 72.33% | 12.02% | 26.42% | - |
| Operating Expenses | 763.29M | 1.02B | 1.64B | 2.73B | 3.8B | 5.46B | 8.24B | 10.93B | 13.84B | 8.15B |
| OpEx % of Revenue | 42.03% | 43.17% | 54.37% | 50.84% | 37.56% | 64.92% | 56.79% | 66.33% | 64.29% | - |
| Selling, General & Admin | 102.41M | 146.99M | 213.69M | 342M | 661M | 1.28B | 2.68B | 3.3B | 3.79B | 2.44B |
| SG&A % of Revenue | 5.64% | 6.21% | 7.06% | 6.37% | 6.54% | 15.24% | 18.45% | 20.01% | 17.61% | - |
| Research & Development | 660.88M | 874.28M | 1.43B | 2.39B | 3.14B | 4.18B | 5.56B | 7.63B | 9.75B | 5.69B |
| R&D % of Revenue | 36.39% | 36.96% | 47.31% | 44.47% | 31.03% | 49.67% | 38.35% | 46.32% | 45.28% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 300M | 1000K |
| Operating Income | 1.05B▲ 0% | 1.34B▲ 27.7% | 1.38B▲ 2.7% | 2.64B▲ 91.1% | 6.31B▲ 139.3% | 2.95B▼ 53.2% | 6.27B▲ 112.2% | 5.32B▼ 15.1% | 6.7B▲ 26.0% | 5.09B▲ 0% |
| Operating Margin % | 57.97% | 56.83% | 45.63% | 49.16% | 62.44% | 35.08% | 43.21% | 32.3% | 31.14% | 36.24% |
| Operating Income Growth % | 44.15% | 27.67% | 2.69% | 91.12% | 139.31% | -53.22% | 112.22% | -15.09% | 25.97% | - |
| EBITDA | 1.09B | 1.41B | 1.47B | 2.78B | 6.56B | 3.2B | 6.63B | 5.56B | 7.12B | 5.31B |
| EBITDA Margin % | 60.23% | 59.78% | 48.53% | 51.75% | 64.87% | 38.05% | 45.7% | 33.76% | 33.06% | 37.83% |
| EBITDA Growth % | 43.5% | 29.29% | 3.81% | 89.17% | 136.19% | -51.17% | 106.96% | -16.11% | 27.96% | 23.64% |
| D&A (Non-Cash Add-back) | 40.96M | 70M | 87.7M | 139M | 246M | 250M | 362M | 240M | 413M | 223.39M |
| EBIT | 1.13B | 1.42B | 1.61B | 2.87B | 5.91B | 3.93B | 6.97B | 5.71B | 9.28B | 5.74B |
| Net Interest Income | 32.37M | 39M | 63M | 113M | 174M | 184M | 303M | 912M | 875M | 328.39M |
| Interest Income | 32.58M | 41M | 62.92M | 120M | 184M | 197M | 324M | 939M | 995M | 447.43M |
| Interest Expense | 213K | 2M | 417K | 7M | 10M | 13M | 21M | 27M | 120M | 119.03M |
| Other Income/Expense | 77.38M | -280.45M | 231.69M | 221M | -409M | 965M | 678M | 316M | 2.46B | 1.92B |
| Pretax Income | 1.13B▲ 0% | 1.06B▼ 5.9% | 1.61B▲ 51.5% | 2.86B▲ 77.4% | 5.9B▲ 106.5% | 3.92B▼ 33.6% | 6.95B▲ 77.3% | 5.64B▼ 18.8% | 9.16B▲ 62.6% | 7.01B▲ 0% |
| Pretax Margin % | 62.23% | 44.97% | 53.29% | 53.28% | 58.39% | 46.55% | 47.88% | 34.22% | 42.57% | 49.92% |
| Income Tax | -56.86M | -39.83M | 139.83M | 693M | 1.15B | 961M | 1.49B | 1.28B | 1.32B | 438.32M |
| Effective Tax Rate % | -5.03% | -3.74% | 8.67% | 24.24% | 19.41% | 24.53% | 21.5% | 22.8% | 14.4% | 6.25% |
| Net Income | 1.19B▲ 0% | 1.1B▼ 7.0% | 1.47B▲ 33.4% | 2.17B▲ 47.1% | 4.76B▲ 119.7% | 2.96B▼ 37.9% | 5.45B▲ 84.4% | 4.35B▼ 20.2% | 7.84B▲ 80.2% | 6.57B▲ 0% |
| Net Margin % | 65.36% | 46.65% | 48.66% | 40.37% | 47.06% | 35.13% | 37.59% | 26.42% | 36.44% | 46.8% |
| Net Income Growth % | 55.48% | -7.04% | 33.4% | 47.13% | 119.67% | -37.85% | 84.38% | -20.18% | 80.24% | 185.54% |
| Net Income (Continuing) | 1.19B | 1.1B | 1.47B | 2.17B | 4.76B | 2.96B | 5.45B | 4.35B | 7.84B | 6.57B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 1.92▲ 0% | 1.78▼ 7.3% | 2.37▲ 33.1% | 3.40▲ 43.5% | 7.22▲ 112.4% | 4.48▼ 38.0% | 8.26▲ 84.4% | 6.60▼ 20.1% | 12.14▲ 83.9% | 10.58▲ 0% |
| EPS Growth % | 52.38% | -7.29% | 33.15% | 43.46% | 112.35% | -37.95% | 84.38% | -20.1% | 83.94% | 45.85% |
| EPS (Basic) | 1.98 | 1.81 | 2.40 | 3.44 | 7.30 | 4.52 | 8.34 | 6.60 | 12.14 | - |
| Diluted Shares Outstanding | 617.66M | 620.94M | 620.45M | 636.37M | 658.86M | 660.46M | 660.1M | 659.15M | 646.33M | 620.74M |
| Basic Shares Outstanding | 598.76M | 608.34M | 612.68M | 629.63M | 651.79M | 653.96M | 653.87M | 659.19M | 646.34M | 615.98M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
GMAB Balance Sheet
Genmab A/S (GMAB) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 4.9B | 6.06B | 7.43B | 13.96B | 18.79B | 22.74B | 28.22B | 33.14B | 27.85B | 4.47B |
| Cash & Short-Term Investments | 3.92B | 5.42B | 6.11B | 10.97B | 16.08B | 19.34B | 22.32B | 28.14B | 21.1B | 3.41B |
| Cash Only | 307.02M | 1.35B | 532.91M | 3.55B | 7.26B | 8.96B | 9.89B | 14.87B | 9.86B | 1.76B |
| Short-Term Investments | 3.61B | 4.08B | 5.57B | 7.42B | 8.82B | 10.38B | 12.43B | 13.27B | 11.24B | 1.65B |
| Accounts Receivable | 975.67M | 579M | 1.33B | 2.99B | 2.46B | 3.37B | 5.71B | 4.95B | 6.69B | 1.05B |
| Days Sales Outstanding | 196.09 | 89.34 | 160.11 | 203.38 | 88.91 | 146.01 | 143.74 | 109.61 | 113.45 | 132.49 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 57M | 62M | 14M |
| Days Inventory Outstanding | - | - | - | - | - | - | - | 92.06 | 22.97 | 27.52 |
| Other Current Assets | 0 | 0 | 0 | 0 | 249M | 31M | 182M | 0 | 0 | 0 |
| Total Non-Current Assets | 340.6M | 543.51M | 1.03B | 1.18B | 2.35B | 1.89B | 1.9B | 2.15B | 17.96B | 2.55B |
| Property, Plant & Equipment | 32.19M | 113.42M | 161.54M | 414M | 736M | 975M | 1.32B | 1.64B | 263.83M | 266M |
| Fixed Asset Turnover | 56.41x | 20.86x | 18.73x | 12.96x | 13.74x | 8.63x | 10.97x | 10.04x | 81.59x | 9.91x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.54B | 355M |
| Intangible Assets | 181.9M | 124.39M | 470.36M | 470M | 338M | 254M | 146M | 101M | 12.34B | 1.75B |
| Long-Term Investments | 1.47M | 8.76M | 9.62M | 149M | 1.08B | 371M | 133M | 134M | 228M | 707.59M |
| Other Non-Current Assets | 0 | 0 | 0 | 11M | 197M | 291M | 300M | 62M | 2.46B | 171.39M |
| Total Assets | 5.24B▲ 0% | 6.6B▲ 26.1% | 8.46B▲ 28.1% | 15.14B▲ 79.0% | 21.14B▲ 39.6% | 24.63B▲ 16.5% | 30.12B▲ 22.3% | 35.29B▲ 17.2% | 45.81B▲ 29.8% | 7.02B▲ 0% |
| Asset Turnover | 0.35x | 0.36x | 0.36x | 0.35x | 0.48x | 0.34x | 0.48x | 0.47x | 0.47x | 0.42x |
| Asset Growth % | 34.23% | 26.05% | 28.14% | 78.99% | 39.61% | 16.48% | 22.3% | 17.17% | 29.82% | -34.74% |
| Total Current Liabilities | 411.54M | 327.12M | 443.35M | 938M | 1.25B | 1.57B | 1.82B | 2.48B | 5.31B | 741M |
| Accounts Payable | 22.27M | 579M | 1.33B | 0 | 0 | 350M | 0 | 0 | 0 | 0 |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 228.15M | 150.65M | 0 | 0 | 0 | 0 | 0 | 33M | 24M | 103.04M |
| Other Current Liabilities | 373.71M | 0 | -651K | 0 | 1.21B | 860M | 1.75B | 0 | 0 | 0 |
| Current Ratio | 11.90x | 18.52x | 16.77x | 14.88x | 15.00x | 14.50x | 15.48x | 13.34x | 5.25x | 5.25x |
| Quick Ratio | 11.90x | 18.52x | 16.77x | 14.88x | 15.00x | 14.50x | 15.48x | 13.32x | 5.24x | 5.24x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 160.02 |
| Total Non-Current Liabilities | 0 | 3.63M | 3.29M | 158M | 769M | 863M | 1.01B | 1.2B | 3.81B | 529M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 155M | 277M | 363M | 523M | 680M | 937M | 2.74B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.36B | 6.87B |
| Other Non-Current Liabilities | 0 | 3.63M | 3.29M | 3M | 492M | 500M | 491M | 35M | 30M | 86.7M |
| Total Liabilities | 411.54M | 330.75M | 446.64M | 1.1B | 2.02B | 2.43B | 2.84B | 3.68B | 9.11B | 1.27B |
| Total Debt | 0 | 0 | 0 | 181M | 319M | 425M | 597M | 770M | 1.03B | 142M |
| Net Debt | -307.02M | -1.35B | -532.91M | -3.37B | -6.94B | -8.53B | -9.3B | -14.1B | -8.83B | -1.62B |
| Debt / Equity | - | - | - | 0.01x | 0.02x | 0.02x | 0.02x | 0.02x | 0.03x | 0.03x |
| Debt / EBITDA | - | - | - | 0.07x | 0.05x | 0.13x | 0.09x | 0.14x | 0.14x | 0.03x |
| Net Debt / EBITDA | -0.28x | -0.95x | -0.36x | -1.21x | -1.06x | -2.66x | -1.40x | -2.53x | -1.24x | -1.24x |
| Interest Coverage | 4942.88x | 672.09x | 3310.03x | 376.86x | 631.30x | 227.15x | 298.43x | 197.07x | 55.86x | 48.21x |
| Total Equity | 4.83B▲ 0% | 6.27B▲ 29.9% | 8.01B▲ 27.8% | 14.05B▲ 75.3% | 19.12B▲ 36.1% | 22.2B▲ 16.1% | 27.28B▲ 22.9% | 31.61B▲ 15.9% | 36.7B▲ 16.1% | 5.75B▲ 0% |
| Equity Growth % | 38.43% | 29.95% | 27.78% | 75.29% | 36.11% | 16.08% | 22.91% | 15.86% | 16.09% | -54.01% |
| Book Value per Share | 7.81 | 10.10 | 12.92 | 22.08 | 29.02 | 33.61 | 41.33 | 47.96 | 56.78 | 9.26 |
| Total Shareholders' Equity | 4.83B | 6.27B | 8.01B | 14.05B | 19.12B | 22.2B | 27.28B | 31.61B | 36.7B | 5.75B |
| Common Stock | 60.35M | 61.19M | 61.5M | 65M | 66M | 66M | 66M | 66M | 66M | 10M |
| Retained Earnings | -3.11B | -1.85B | -197.46M | 2.13B | 7.11B | 10.02B | 14.81B | 19.02B | 23.55B | 4.03B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 102.88M | 82.08M | 91.71M | 98M | 54M | 81M | 98M | 60M | 490M | -204M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GMAB Cash Flow Statement
Genmab A/S (GMAB) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 327.72M | 1.59B | 1.01B | 1.33B | 6.43B | 2.23B | 3.91B | 7.38B | 7.77B | 7.77B |
| Operating CF Margin % | 18.05% | 67.17% | 33.55% | 24.71% | 63.62% | 26.47% | 26.97% | 44.8% | 36.1% | - |
| Operating CF Growth % | 5.22% | 384.86% | -36.14% | 30.67% | 385.14% | -65.37% | 75.58% | 88.65% | 5.3% | 715.7% |
| Net Income | 1.13B | 1.06B | 1.61B | 2.86B | 4.76B | 3.98B | 7.04B | 5.64B | 7.84B | 6.57B |
| Depreciation & Amortization | 40.96M | 69.75M | 87.6M | 139M | 266M | 248M | 362M | 295M | 413M | 241.09M |
| Stock-Based Compensation | 53.19M | 75.98M | 90.76M | 147M | 200M | 310M | 439M | 586M | 721M | 433.44M |
| Deferred Taxes | 39.61M | -140.58M | 90.52M | -385M | 0 | -546M | 0 | 122M | 0 | 0 |
| Other Non-Cash Items | -77.38M | 280.45M | -231.69M | -216M | 903M | -997M | -1.99B | -622M | 388M | -2.6B |
| Working Capital Changes | -858.87M | 239.65M | -634.37M | -1.22B | 306M | -770M | -1.93B | 1.36B | -1.59B | -137.85M |
| Change in Receivables | -794.93M | 270.35M | -768.15M | -1.66B | 306M | -1.07B | -2.12B | 797M | -1.59B | -500.26M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -57M | -5M | -26.47M |
| Change in Payables | 0 | 0 | 133.78M | 440M | 0 | 304M | 283M | 622M | 0 | 0 |
| Cash from Investing | -1.01B | -667.57M | -1.78B | -1.98B | -2.35B | -961M | -2.76B | -1.28B | -9.91B | -67.42M |
| Capital Expenditures | -33.11M | -88.51M | -477.37M | -111M | -307M | -252M | -317M | -366M | -187M | -159.06M |
| CapEx % of Revenue | 1.82% | 3.74% | 15.78% | 2.07% | 3.04% | 2.99% | 2.19% | 2.22% | 0.87% | - |
| Acquisitions | 20.86M | 0 | 405.67M | 32M | 0 | 709M | 2.44B | 0 | -12.25B | 125.71M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -20.86M | -579.06M | -405.67M | -32M | -2.04B | -709M | -2.44B | -10M | -117M | -137.12M |
| Cash from Financing | 91.19M | 214.91M | -70.9M | 3.66B | 71M | -420M | -789M | -606M | -3.92B | -2.64B |
| Debt Issued (Net) | -118K | 0 | 0 | -31M | -44M | -58M | -73M | -91M | -60M | -43.32M |
| Equity Issued (Net) | -1000K | 0 | -1000K | 1000K | -1000K | -1000K | -1000K | -1000K | -1000K | -2M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -118.1M | 0 | -146M | 0 | -25M | -447M | -908M | -564M | -3.99B | -3.12B |
| Other Financing | 209.41M | 214.91M | 75.1M | -182M | 140M | 85M | 192M | 49M | 129M | 521.34M |
| Net Change in Cash | -566.96M▲ 0% | 1.04B▲ 283.5% | -814.64M▼ 178.3% | 3.02B▲ 470.6% | 3.71B▲ 22.8% | 1.7B▼ 54.2% | 936M▼ 44.8% | 4.97B▲ 431.4% | -5.01B▼ 200.7% | 467.44M▲ 0% |
| Free Cash Flow | 294.61M▲ 0% | 1.5B▲ 409.3% | 537.42M▼ 64.2% | 1.22B▲ 126.1% | 6.13B▲ 404.2% | 1.98B▼ 67.7% | 3.6B▲ 81.9% | 7B▲ 94.8% | 7.58B▲ 8.3% | 2.91B▲ 0% |
| FCF Margin % | 16.22% | 63.43% | 17.77% | 22.64% | 60.59% | 23.48% | 24.78% | 42.52% | 35.23% | 20.72% |
| FCF Growth % | 67.33% | 409.3% | -64.18% | 126.08% | 404.2% | -67.74% | 81.93% | 94.83% | 8.28% | -27.63% |
| FCF per Share | 0.48 | 2.42 | 0.87 | 1.91 | 9.30 | 2.99 | 5.45 | 10.63 | 11.73 | 11.73 |
| FCF Conversion (FCF/Net Income) | 0.28x | 1.44x | 0.69x | 0.61x | 1.35x | 0.75x | 0.72x | 1.70x | 0.99x | 0.44x |
| Interest Paid | 0 | 0 | 0 | 0 | 20M | 0 | 0 | 0 | 35M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GMAB Key Ratios
Genmab A/S (GMAB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 28.56% | 19.89% | 20.61% | 19.64% | 28.69% | 14.31% | 22.04% | 14.78% | 22.97% | 114.25% |
| Return on Invested Capital (ROIC) | 22.14% | 21.35% | 16.69% | 21.79% | 41.43% | 17.14% | 29.7% | 22.48% | 22.16% | 22.16% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 98.63% | 95.42% | 94.31% |
| Net Margin | 65.36% | 46.65% | 48.66% | 40.37% | 47.06% | 35.13% | 37.59% | 26.42% | 36.44% | 46.8% |
| Debt / Equity | - | - | - | 0.01x | 0.02x | 0.02x | 0.02x | 0.02x | 0.03x | 0.03x |
| Interest Coverage | 4942.88x | 672.09x | 3310.03x | 376.86x | 631.30x | 227.15x | 298.43x | 197.07x | 55.86x | 48.21x |
| FCF Conversion | 0.28x | 1.44x | 0.69x | 0.61x | 1.35x | 0.75x | 0.72x | 1.70x | 0.99x | 0.44x |
| Revenue Growth | 60.29% | 30.25% | 27.89% | 77.38% | 88.43% | -16.75% | 72.33% | 13.57% | 30.67% | 21.03% |
GMAB Frequently Asked Questions
Genmab A/S (GMAB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Genmab A/S (GMAB) reported $14.04B in revenue for fiscal year 2024.
Genmab A/S (GMAB) grew revenue by 30.7% over the past year. This is strong growth.
Yes, Genmab A/S (GMAB) is profitable, generating $6.57B in net income for fiscal year 2024 (36.4% net margin).
Dividend & Returns
Genmab A/S (GMAB) has a return on equity (ROE) of 23.0%. This is excellent, indicating efficient use of shareholder capital.
Genmab A/S (GMAB) generated $2.91B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More GMAB
Genmab A/S (GMAB) financial analysis — history, returns, DCA and operating performance tools
Full GMAB Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates